- AstraZeneca (AZN) reported six positive Phase III readouts and gained initial regulatory approvals for multiple new molecular entities, signaling pipeline momentum relevant for traders.
- AstraZeneca’s SONE-VE showed overall survival benefit in CLDN18.2-positive advanced gastric and gastroesophageal junction cancer patients in second‑line and later settings, per company announcement.
- AstraZeneca said Ultomiris missed statistical significance for 26‑week event‑free survival in a late‑stage HSCT‑TMA trial; data showed a trend to benefit and discussions with regulators are ongoing.
- AstraZeneca licensed TQC3721 (PDE3/4 inhibitor) from Sino Biopharm’s CTIQ for respiratory uses. Deal: $200M upfront, up to $1.9B milestones, plus double‑digit tiered royalties.
TradingView
Key facts: AZN posts six Phase III wins; SONE‑VE OS; Ultomiris misses
- Sources
- TradingView
- Active symbols
- LSE:AZN
- Language
- English (India)
AstraZeneca (AZN) reported six positive Phase III readouts and gained initial regulatory approvals for multiple new molecular entities, signaling pipeline momentum relevant for tra